AzTrials
AzTrials

Type 2 DiabetesPROMOTENCT07181304

Peer Support and Remote Patient Monitoring for Black Adults With Type 2 Diabetes

A study testing PROMOTE and DSMES in people with Type 2 Diabetes, run by University of Alabama at Birmingham at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study will include a type 1 hybrid effectiveness implementation study to evaluate the effectiveness of the PROMOTE (peer support plus remote patient monitoring) program among Black adults with uncontrolled type 2 diabetes recruited from local primary care practices in Jefferson County, Alabama. Read more about this study

Who is it for?
Ages 19 years and older
Conditions the study is for
Type 2 Diabetes
What is being tested?
PROMOTE and DSMES
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteUnited States
Study dates
30 Nov 2026to 30 Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 19 years or older
  • Black race (self-reported)
  • Diagnosis of type 2 diabetes
  • Uncontrolled A1C >8%
  • Receipt of care at one of the study sites
  • Speaks and reads in English

Who cannot join

  • Limited English proficiency
  • Currently pregnancy
  • Non-community dwelling.
  • Speaks and reads in English

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Caroline Presley, MD contact

12059347609

capresley@uabmc.edu

United States1 site
  • Cooper Green Mercy Health System

    Birmingham, Alabama, 35294

    Raegan Durant, MD, (205) 930-3200, rdurant@uabmc.edu

Other trials in United States

About this study

Official title: Peer Support and Remote Patient Monitoring for Black Adults With Type 2 Diabetes: PROMOTE Study

This study will include a type 1 hybrid effectiveness implementation study to evaluate the effectiveness of the PROMOTE (peer support plus remote patient monitoring) program among Black adults with uncontrolled type 2 diabetes recruited from local primary care practices in Jefferson County, Alabama. Additionally, a mixed methods evaluation to characterize the contextual factors relevant to implementation of PROMOTE using Practical Robust Implementation Science Model (PRISM) will be conducted.

Read the detailed description

In the proposed study, the study team will conduct a type 1 hybrid effectiveness-implementation randomized controlled trial (RCT) of peer support plus remote patient monitoring as well as a mixed methods evaluation of contextual factors relevant to program delivery and implementation. Black adults with uncontrolled type 2 diabetes (A1C >8%) from primary care practices in Jefferson County, Alabama will be recruited to participate in this RCT.

Specific Aim 1: To evaluate the effectiveness of the PROMOTE (peer support plus remote patient monitoring) program among Black adults with uncontrolled type 2 diabetes in Jefferson County, Alabama. Hypothesis: The PROMOTE program will be effective, leading to clinically meaningful improvements in glycemic control.

A type 1 hybrid effectiveness-implementation RCT among Black adults with uncontrolled type 2 diabetes (A1C >8%) will test the PROMOTE program. The study team will be working with primary care practices in Jefferson County, Alabama through a consortium of community-based primary care providers who aim to improve healthcare delivery and outcomes by integrating research into their daily practice of medicine. Participants will be randomized 1:1 to intervention (PROMOTE) or control condition. Both study arms will receive diabetes self-management education and support (DSMES) delivered virtually. Participants randomized to the PROMOTE program will receive core components of peer support, remote patient monitoring of blood glucose, and integration with clinical care. Peer support will be delivered by trained ConnectionHealth CHWs with an initial in-person visit, followed by phone visits weekly for 3 months, then monthly for 3 months. ConnectionHealth is a 501c3 nonprofit organization that was founded in December 2014 in Birmingham, Alabama dedicated to training and deploying community health workers (CHWs) to address the needs of Alabama's most vulnerable citizens. Currently, ConnectionHealth serves citizens in Jefferson County, Shelby County, and the Black Belt Region of rural Alabama, providing community-based support with the goal of assisting clients to achieve healthier lives. The study team will partner with UAB eMedicine to deliver remote patient monitoring program. UAB eMedicine has an active remote patient monitoring program that is currently monitoring over 900 patients. All glucose values are transmitted via cellular enabled devices; the patients do not need access to their own internet plan or to their own smart device, which ensures that there are no disparities related to the technology. Furthermore, test strips are provided to patients on a regular basis by the program based on the number of readings performed, which eliminates a barrier of cost. Participants will be asked to check blood glucose with remote patient monitoring daily for 6 months, frequency tailored to their medication regimen. Monthly reports of peer support and remote patient monitoring activities will be provided to primary care providers. Clinical and patient-reported outcomes will include change from baseline to 6 months for the following: A1C (primary), as well as secondary outcomes of blood pressure, low density lipoprotein levels, body mass index, diabetes self-management, and diabetes distress. Clinical outcome will be extracted from the electronic health record and patient reported outcomes will be obtained via patient survey using validated measures. The main analysis will used linear mixed effects models to model change in each outcome (e.g. A1C) by study group (intervention vs. control arms), adjusted for the baseline value, accounting for any meaningful clustering using random intercepts. The hypotheses of an intervention effect will be tested by the significance of the coefficient for study group at the p<0.05 level.

Specific Aim 2: To characterize the contextual factors relevant to implementation of PROMOTE using Practical Robust Implementation Science Model (PRISM) through mixed methods evaluation.

PRISM is a context-oriented framework that aligns well with this study because it is intended to be used across program phases from pre-implementation, implementation, evaluation, and sustainment phases with a focus on the contextual domains closely tied to the outcomes of the RE-AIM framework (Reach Effectiveness Adoption Implementation and Maintenance). The study team will use purposeful recruitment to identify provider participants with a goal of 2-4 key informant provider participants per site with the following roles represented including physicians and advanced practice providers, nurses, care coordinators, and administrative staff. The study team will use parallel convergent mixed methods utilizing PRISM to assess perspectives and characteristics at the organizational and patient levels, as well as implementation and sustainability infrastructure and external environment, to determine key contextual factors that serve as implementation determinants.23 These results will be applied to determine future implementation strategies.

Conditions
Type 2 Diabetes
Being tested
PROMOTE, DSMES
Keywords
Peer support, Remote patient monitoring
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PROMOTEBehavioural

    PROMOTE components includes 1) peer support, 2) remote patient monitoring of blood glucose (RPM), and 3) integration with clinical care.

    1. Peer support delivered by community health workers focused on -- assistance in applying diabetes self-management in daily life, emotional and social support, linkage to clinical care, and ongoing, as-needed support. CHWs visits will include: one-on-one in-person visit, then weekly phone calls for 3 months, then monthly calls for 3 months.
    2. RPM team will supply the device and supplies to participants. Data is transmitted electronically to the RPM team through broadband connectivity. Protocols have been developed for research projects; participants will be instructed to monitor blood glucose up to four times a day, based on medication regimen. Levels will be monitored 8 a.m. to 5 p.m. M-F.
    3. A monthly report of peer support activities and RPM data will be sent to participants' primary care providers.
  • DSMESBehavioural

    Diabetes Self-Management Education and Support delivered virtually.

Study groups in NCT07181304
Study groupRoleWhat they receive
PROMOTEExperimentalNot described
Receives: Behavioral: PROMOTE; Behavioral: DSMES
ControlActive comparatorNot described
Receives: Behavioral: DSMES

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Hemoglobin A1c (A1C)

    Change in A1C value at 6-months compared to baseline. Lab values will be extracted from electronic health record. Per the American Diabetes Association (ADA) Standards of Care, A1C is recommended to be checked quarterly for patients with type 2 diabetes, whose A1C is not at target level (i.e. the eligibility criteria for this study sample).

    Measured: Baseline, 6-months

Secondary outcomes (3)
  1. Change in blood pressure

    Biometric data will be extracted from electronic health record by study personnel. Blood pressure is recommended to be checked at each followup visit for patients with type 2 diabetes; recommended follow-up visit frequency of every 3 months for patients whose A1C is not at the target level.

    Measured: Baseline, 6-months

  2. Change in Low Density Lipoprotein (LDL)

    Laboratory data will be extracted from electronic health record by study personnel. Per the American Diabetes Association (ADA) Standards of Care, LDL is recommended to be checked annually for patients with type 2 diabetes

    Measured: Baseline, 6-months

  3. Change in Body Mass Index (BMI)

    Biometric data will be extracted from electronic health record by study personnel. BMI is recommended to be measured at each followup visit for patients with type 2 diabetes; recommended follow-up visit frequency of every 3 months for patients whose A1C is not at the target level.

    Measured: Baseline, 6-months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2025
  2. Study start30 Nov 2026 (estimated)
  3. Primary completion30 Jun 2028 (estimated)
  4. Study completion30 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07181304
Sponsor's protocol ID
IRB-300015327
Other IDs
7-25-ICTSPC-410
Acronym
PROMOTE
Status last verified
Oct 2026
First submitted
11 Sep 2025
Last updated
30 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified Individual Participant Data for the following measures will be restricted with a data use agreement: 1) Biometric and lab data including hemoglobin A1c, height, weight, body mass index, blood pressure, remote monitoring of blood glucose; 2) Demographics and health status per NIH required common data elements; 3) Survey assessment: Diabetes Distress Scale, Patient Health Questionnaire, Diabetes Self-Management Questionnaire, Diabetes Self-Efficacy, and Social Support

Questions about this trial

What is this clinical trial studying?

A study testing PROMOTE and DSMES in people with Type 2 Diabetes, run by University of Alabama at Birmingham at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Caroline Presley, MD (12059347609, capresley@uabmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Hemoglobin A1c (A1C) (time frame: Baseline, 6-months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in